Table of frequent aberrant markers in AML: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
| Line 12: | Line 12: | ||
----- | ----- | ||
Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage | Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage | ||
CD2 CD4, 36 38 MONOCYTIC 5% | CD2 CD4, 36 38 MONOCYTIC 5% | ||
Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: | Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: | ||
| Line 24: | Line 20: | ||
CD56 CBF RUNX1 | CD56 CBF RUNX1 | ||
NPM1 OFTEN LACK CD34 | NPM1 OFTEN LACK CD34 | ||
---- | |||
Revision as of 17:24, 12 January 2024
The key point is that AML will frequently express immunological markers not typically associated with myeloid lineage. This is aknowledged in diagnostic criteria and providing diagnostic criteria are applied they do not require a change in diagnosis.
The most frequent "abberencies" observed in AML are
(1) The expression of CD7 by nearly half of cases
(2) The expression of CD19 (often associated with particular AML subtypes)
Markers associated with lymphoid maturation that may also be expressed by the lineage maturation, particularly monocytic lineage CD2 CD4, 36 38 MONOCYTIC 5%
Frequent abberant markers in AML that are often associated with genetic/cytogenetic subtype: CD19 30% CBF RUNX1, BCRABL CD56 CBF RUNX1 NPM1 OFTEN LACK CD34